Adamalizyny jako potencjalne biomarkery w wybranych nowotworach złośliwych przewodu pokarmowego

Magdalena Sikora-Skrabaka; Katarzyna Walkiewicz; Ewa Nowakowska-Zajdel

doi:10.2478/ahem-2021-0020

.blurhash-client-img { display: none !important; }

Adamalizyny jako potencjalne biomarkery w wybranych nowotworach złośliwych przewodu pokarmowego

Postępy Higieny i Medycyny Doświadczalnej

Volume 75 (2021): Issue 1 (January 2021)

By: Magdalena Sikora-Skrabaka, Katarzyna Walkiewicz and Ewa Nowakowska-Zajdel

Open Access

|Oct 2021

Abstract

Gastrointestinal cancers are one of the most common causes of cancers and cancer-related mortality worldwide. Potential biomarkers that could serve as predictive and prognostic factors in these cancers are still being sought. Adamalysines are mentioned among the proteins that could play such a role. Numerous proteins from this family are involved in the many stages of tumor formation: from the process of individual cell differentiation, through tumor growth and progression, to the formation of distant metastases. This process occurs, among others, through signaling pathways associated with the activation of insulin-like growth factors, epidermal growth factors or the effect on tumor necrosis factor TNF-α. The signal pathway associated with the activation of proinflammatory cytokines seems to be particularly important in explaining the pathomechanism of gastrointestinal adenocarcinomas. Chronic inflammation is a well-documented risk factor for the development of this group of cancer diseases.

Understanding the role of adamalysines protein family in the development and pathogenesis of gastrointestinal malignancies still requires further research. The article attempts to synthesize current knowledge on the use of selected proteins from the adamalysin family as biomarkers for gastrointestinal cancers.

References

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A.: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018; 68: 394-424
Open DOI Search in Google Scholar Back to article
Duffy M.J., McKiernan E., O’Donovan N., McGowan P.M.: Role of ADAMs in cancer formation and progression. Clin. Cancer Res., 2009; 15: 1140-1144
Open DOI Search in Google Scholar Back to article
Walkiewicz K., Kozieł P., Bednarczyk M., Błażelonis A., Mazurek U., Muc-Wierzgoń M.: Expression of migration-related genes in human colorectal cancer and activity of a disintegrin and metalloproteinase 17. Biomed Res. Int., 2016; 2016: 8208904
Open DOI Search in Google Scholar Back to article
Walkiewicz K., Nowakowska-Zajdel E., Kozieł P., Muc-Wierzgoń M.: The role of some ADAM-proteins and activation of the insulin growth factor-related pathway in colorectal cancer. Cent. Eur. J. Immunol., 2018; 43: 109-113
Open DOI Search in Google Scholar Back to article
Fushida S., Oyama K., Kinoshita J., Yagi Y., Okamoto K., Tajima H., Ninomiya I., Fujimura T., Ohta T.: VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: Prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody. Onco. Targets Ther., 2013; 6: 14451451
Open DOI Search in Google Scholar Back to article
Gao M.Q., Kim B.G., Kang S., Choi Y.P., Yoon J.H., Cho N.H.: Human breast cancer-associated fibroblasts enhance cancer cell proliferation through increased TGF-α cleavage by ADAM17. Cancer Lett., 2013; 336: 240-246
Open DOI Search in Google Scholar Back to article
Mochizuki S., Okada Y.: ADAM28 as a target for human cancers. Curr. Pharm. Des., 2009; 15: 2349-2358
Open DOI Search in Google Scholar Back to article
Stawikowska R., Cudic M., Giulianotti M., Houghten R.A., Fields G.B., Minond D.: Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates. J. Biol. Chem., 2013; 288: 22871-22879
Open DOI Search in Google Scholar Back to article
Jones J.C., Rustagi S., Dempsey P.J.: ADAM proteases and gastrointestinal function. Annu. Rev. Physiol., 2016; 78: 243-276
Open DOI Search in Google Scholar Back to article
Zhou Z., Ran Y.L., Hu H., Pan J., Li Z.F., Chen L.Z., Sun L.C., Peng L., Zhao X.L., Yu L. i wsp.: TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression. Clin. Exp. Metastasis, 2008; 25: 537-548
Open DOI Search in Google Scholar Back to article
Liu H.B., Zhu Y., Yang Q.C., Shen Y., Zhang X.J., Chen H.: Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma. Genet. Mol. Res., 2015; 14: 43914398
Open DOI Search in Google Scholar Back to article
Lo P.H., Lung H.L., Cheung A.K., Apte S.S., Chan K.W., Kwong F.M., Ko J.M., Cheng Y., Law S., Srivastava G. i wsp.: Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res., 2010; 70: 5567-5576
Open DOI Search in Google Scholar Back to article
Kauttu T., Mustonen H., Vainionpää S., Krogerus L., Ilonen I., Räsänen J., Salo J., Puolakkainen P.: Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma. Clin. Transl. Oncol., 2017; 19: 58-66
Open DOI Search in Google Scholar Back to article
Yoshimura T., Tomita T., Dixon M.F., Axon A.T., Robinson P.A., Crabtree J.E.: ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori – infected, normal, and neoplastic gastric mucosa. J. Infect. Dis., 2002; 185: 332-340
Open DOI Search in Google Scholar Back to article
Wang Y.Y., Ye Z.Y., Li L., Zhao Z.S., Shao Q.S., Tao H.Q.: ADAM 10 is associated with gastric cancer progression and prognosis of patients. J. Surg. Oncol., 2011; 103: 116-123
Open DOI Search in Google Scholar Back to article
Shou Z.X., Jin X., Zhao Z.S.: Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Ann. Surg., 2012; 256: 1014-1022
Open DOI Search in Google Scholar Back to article
Zhang T.C., Zhu W.G., Huang M.D., Fan R.H., Chen X.F.: Prognostic value of ADAM17 in human gastric cancer. Med. Oncol., 2012; 29: 2684-2690
Open DOI Search in Google Scholar Back to article
Aydin D., Bilici A., Yavuzer D., Kefeli U., Tan A., Ercelep O., Mert A., Yuksel S., Ozcelik M., Isik D. i wsp.: Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy. Clin. Transl. Oncol., 2015; 17: 604-611
Open DOI Search in Google Scholar Back to article
Li W., Wang D., Sun X., Zhang Y., Wang L., Suo J.: ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways. Int. J. Mol. Med., 2019; 43: 914-926
Open DOI Search in Google Scholar Back to article
Ebi M., Kataoka H., Shimura T., Kubota E., Hirata Y., Mizushima T., Mizoshita T., Tanaka M., Mabuchi M., Tsukamoto H. i wsp.: TGFβ induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cells. Biochem. Biophys. Res. Commun., 2010; 402: 449-454
Open DOI Search in Google Scholar Back to article
Nakagawa M., Nabeshima K., Asano S., Hamasaki M., Uesugi N., Tani H., Yamashita Y., Iwasaki H.: Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: Coexpression with EGFR and EGFR ligands. Cancer Sci., 2009; 100: 654-662
Open DOI Search in Google Scholar Back to article
Carl-McGrath S., Lendeckel U., Ebert M., Roessner A., Röcken C.: The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int. J. Oncol., 2005; 26: 17-24
Open DOI Search in Google Scholar Back to article
Kim K.E., Song H., Hahm C., Yoon S.Y., Park S., Lee H.R., Hur D.Y., Kim T., Kim C.H., Bang S.I. i wsp.: Expression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancer. J. Immunol., 2009; 182: 3548-3555
Open DOI Search in Google Scholar Back to article
Kim J.M., Jeung H.C., Rha S.Y., Yu E.J., Kim T.S., Shin Y.K., Zhang X., Park K.H., Park S.W., Chung H.C. i wsp.: The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. Mol. Cancer Ther., 2014; 13: 3074-3085
Open DOI Search in Google Scholar Back to article
Wang J., Zhou Y., Fei X., Chen X., Yan J., Liu B., Zhu Z.: ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126. Oncol. Rep., 2017; 37: 2033-2040
Open DOI Search in Google Scholar Back to article
Huang J., Bai Y., Huo L., Xiao J., Fan X., Yang Z., Chen H., Yang Z.: Upregulation of a disintegrin and metalloprotease 8 is associated with progression and prognosis of patients with gastric cancer. Transl. Res., 2015; 166: 602-613
Open DOI Search in Google Scholar Back to article
Chung H.W., Kim J.J., Choi J.I., Lee H.R., Lim J.B.: A disintegrin and metalloproteinase 8 as a potential blood biomarker for early diagnosis of gastric cancer. Yonsei Med. J., 2019; 60: 713-719
Open DOI Search in Google Scholar Back to article
Chen H., Wang S.: Clinical significance of ADAM29 promoting the invasion and growth of gastric cancer cells in vitro. Oncol. Lett., 2018; 16: 1483-1490
Open DOI Search in Google Scholar Back to article
Ilic M, Ilic I.: Epidemiology of pancreatic cancer. World J. Gastroenterol., 2016; 22: 9694-9705
Open DOI Search in Google Scholar Back to article
Stewart B.W., Wild C.P.: World cancer report 2014. International Agency for Research on Cancer, Lyon 2014
Search in Google Scholar Back to article
Gaida M.M., Haag N., Günther F., Tschaharganeh D.F., Schirmacher P., Friess H., Giese N.A., Schmidt J., Wente M.N.: Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int. J. Mol. Med., 2010; 26: 281-288
Open DOI Search in Google Scholar Back to article
Ringel J., Jesnowski R., Moniaux N., Lüttges J., Ringel J., Choudhury A., Batra S.K., Klöppel G., Löhr M.: Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-α converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res., 2006; 66: 9045-9053
Open DOI Search in Google Scholar Back to article
Valkovskaya N., Kayed H., Felix K., Hartmann D., Giese N.A., Osinsky S.P., Friess H., Kleeff J.: ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J. Cell. Mol. Med., 2007; 11: 1162-1174
Open DOI Search in Google Scholar Back to article
Valkovskaya N.V: Hypoxia-dependent expression of ADAM8 in human pancreatic cancer cell lines. Exp. Oncol., 2008; 30: 129132
Search in Google Scholar Back to article
Puolakkainen P., Koski A., Vainionpää S., Shen Z., Repo H., Kemppainen E., Mustonen H., Seppänen H.: Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression. Med. Oncol., 2014; 31: 884
Open DOI Search in Google Scholar Back to article
Gao Y., Yu X., Zhang F., Dai J.: Propofol inhibits pancreatic cancer progress under hypoxia via ADAM8. J. Hepatobiliary Pancreat. Sci., 2019; 26: 219-226
Open DOI Search in Google Scholar Back to article
Grützmann R., Lüttges J., Sipos B., Ammerpohl O., Dobrowolski F., Alldinger I., Kersting S., Ockert D., Koch R., Kalthoff H. i wsp.: ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br. J. Cancer, 2004; 90: 1053-1058
Open DOI Search in Google Scholar Back to article
Oria V.O., Lopatta P., Schmitz T., Preca B.T., Nyström A., Conrad C., Bartsch J.W., Kulemann B., Hoeppner J., Maurer J. i wsp.: ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma. Mol. Oncol., 2019; 13: 456-479
Open DOI Search in Google Scholar Back to article
Duan X., Mao X., Sun W.: ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells. Mol. Med. Rep., 2013; 7: 991-997
Open DOI Search in Google Scholar Back to article
Woods N., Trevino J., Coppola D., Chellappan S., Yang S., Padmanabhan J.: Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling. Oncotarget, 2015; 6: 35931-35948
Open DOI Search in Google Scholar Back to article
Ye J., Yuen S.M., Murphy G., Xie R., Kwok H.F.: Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 antibody in a pancreatic cancer model in vivo. Eur. J. Pharm. Sci., 2017; 110: 62-69
Open DOI Search in Google Scholar Back to article
Schlomann U., Koller G., Conrad C., Ferdous T., Golfi P., Garcia A.M., Höfling S., Parsons M., Costa P., Soper R. i wsp.: ADAM8 as a drug target in pancreatic cancer. Nat. Commun., 2015; 6: 6175
Open DOI Search in Google Scholar Back to article
Moss M.L., Minond D.: Recent advances in ADAM17 research: A promising target for cancer and inflammation. Mediators Inflamm., 2017; 2017: 9673537
Open DOI Search in Google Scholar Back to article
Terzić J., Grivennikov S., Karin E., Karin M.: Inflammation and colon cancer. Gastroenterology, 2010; 138: 2101-2114
Open DOI Search in Google Scholar Back to article
Blanchot-Jossic F., Jarry A., Masson D., Bach-Ngohou K., Paineau J., Denis M.G., Laboisse C.L., Mosnier J.F.: Up-regulated expression of ADAM17 in human colon carcinoma: Co-expression with EGFR in neoplastic and endothelial cells. J. Pathol., 2005; 207: 156-163
Open DOI Search in Google Scholar Back to article
Das S., Czarnek M., Bzowska M., Mężyk-Kopeć R., Stalińska K., Wyroba B., Sroka J., Jucha J., Deneka D., Stokłosa P. i wsp.: ADAM17 silencing in mouse colon carcinoma cells: The effect on tumoricidal cytokines and angiogenesis. PLoS One, 2012; 7: e50791
Open DOI Search in Google Scholar Back to article
Lin H.M., Chatterjee A., Lin Y.H., Anjomshoaa A., Fukuzawa R., McCall J.L., Reeve A.E.: Genome wide expression profiling identifies genes associated with colorectal liver metastasis. Oncol. Rep., 2007; 17: 1541-1549
Open DOI Search in Google Scholar Back to article
Van Schaeybroeck S., Kyula J.N., Fenton A., Fenning C.S., Sasazuki T., Shirasawa S., Longley D.B., Johnston P.G.: Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. Cancer Res., 2011; 71: 1071-1080
Open DOI Search in Google Scholar Back to article
Rios-Doria J., Sabol D., Chesebrough J., Stewart D., Xu L., Tammali R., Cheng L., Du Q., Schifferli K., Rothstein R. i wsp.: A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR-mediated pathways. Mol. Cancer Ther., 2015; 14: 1637-1649
Open DOI Search in Google Scholar Back to article
Dempsey P.J.: Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis. Biochim. Biophys. Acta, 2017; 1864: 22282239
Open DOI Search in Google Scholar Back to article
Knösel T., Emde A., Schlüns K., Chen Y., Jürchott K., Krause M., Dietel M., Petersen I.: Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia, 2005; 7: 741-747
Open DOI Search in Google Scholar Back to article
Walkiewicz K., Strzelczyk J., Waniczek D., Biernacki K., Muc-Wierzgoń M., Copija A., Nowakowska-Zajdel E.: Adamalysines as biomarkers and a potential target of therapy in colorectal cancer patients: Preliminary results. Dis. Markers, 2019; 2019: 5035234
Open DOI Search in Google Scholar Back to article
Nowakowska-Zajdel E., Mazurek U., Wierzgoń J., Kokot T., Fatyga E., Ziółko E., Klakla K., Błazelonis A., Waniczek D., Głogowski Ł. i wsp.: Expression of ADAM28 and IGFBP-3 genes in patients with colorectal cancer – a preliminary report. Int. J. Immunopathol. Pharmacol., 2013; 26: 223-228
Open DOI Search in Google Scholar Back to article
Mochizuki S., Ao T., Sugiura T., Yonemura K., Shiraishi T., Kajiwara Y., Okamoto K., Shinto E., Okada Y., Ueno H.: Expression and function of a disintegrin and metalloproteinases in cancerassociated fibroblasts of colorectal cancer. Digestion, 2020; 101: 18-24
Open DOI Search in Google Scholar Back to article
Yang Z., Bai Y., Huo L., Chen H., Huang J., Li J., Fan X., Yang Z., Wang L., Wang J.: Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer. BMC Cancer, 2014; 14: 568
Open DOI Search in Google Scholar Back to article
Hirao T., Nanba D., Tanaka M., Ishiguro H., Kinugasa Y., Doki Y., Yano M., Matsuura N., Monden M., Higashiyama S.: Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp. Cell Res., 2006; 312: 331-339
Open DOI Search in Google Scholar Back to article
Mazzocca A., Coppari R., De Franco R., Cho J.Y., Libermann T.A., Pinzani M., Toker A.: A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res., 2005; 65: 4728-4738
Open DOI Search in Google Scholar Back to article
Toquet C., Colson A., Jarry A., Bezieau S., Volteau C., Boisseau P., Merlin D., Laboisse C.L., Mosnier J.F.: ADAM15 to α5β1 integrin switch in colon carcinoma cells: A late event in cancer progression associated with tumor dedifferentiation and poor prognosis. Int. J. Cancer, 2012; 130: 278-287
Open DOI Search in Google Scholar Back to article
Wang J., Li H., Wang Y., Wang L., Yan X., Zhang D., Ma X., Du Y., Liu X., Yang Y.: MicroRNA-552 enhances metastatic capacity of colorectal cancer cells by targeting a disintegrin and metalloprotease 28. Oncotarget, 2016; 7: 70194-70210
Open DOI Search in Google Scholar Back to article
Li L.X., Lam I.H., Liang F.F., Yi S.P., Ye L.F., Wang J.T., Guo W.W., Xu M.: MiR-198 affects the proliferation and apoptosis of colorectal cancer through regulation of ADAM28/JAK-STAT signaling pathway. Eur. Rev. Med. Pharmacol. Sci., 2019; 23: 1487-1493
Search in Google Scholar Back to article
Zhang Q., Yu L., Qin D., Huang R., Jiang X., Zou C., Tang Q., Chen Y., Wang G., Wang X., Gao X.: Role of microRNA-30c targeting ADAM19 in colorectal cancer. PLoS One, 2015; 10: e0120698
Open DOI Search in Google Scholar Back to article
Fu Q., Cheng J., Zhang J., Zhang Y., Chen X., Luo S., Xie J.: MiR-20b reduces 5-FU resistance by suppressing the ADAM9/ EGFR signaling pathway in colon cancer. Oncol. Rep., 2017; 37: 123-130
Open DOI Search in Google Scholar Back to article
Carloni V., Mazzocca A., Mello T., Galli A., Capaccioli S.: Cell fusion promotes chemoresistance in metastatic colon carcinoma. Oncogene, 2013; 32: 2649-2660
Open DOI Search in Google Scholar Back to article
Kyula J.N., Van Schaeybroeck S., Doherty J., Fenning C.S., Longley D.B., Johnston P.G.: Chemotherapy-induced activation of ADAM-17: A novel mechanism of drug resistance in colorectal cancer. Clin. Cancer Res., 2010; 16: 3378-3389
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/ahem-2021-0020 | Journal eISSN: 1732-2693

Journal RSS Feed

Language: English, Polish

Page range: 674 - 682

Submitted on: May 5, 2020

Accepted on: May 25, 2021

Published on: Oct 21, 2021

Published by: Hirszfeld Institute of Immunology and Experimental Therapy

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

adamalisynes,

gastrointestinal cancers,

biomarkers

Related subjects:

Life sciences,

Molecular biology,

Microbiology and virology,

Medicine,

Basic medical science,

Immunology

© 2021 Magdalena Sikora-Skrabaka, Katarzyna Walkiewicz, Ewa Nowakowska-Zajdel, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 75 (2021): Issue 1 (January 2021)